Analysis of IVF Success Rates for Recurrent Implantation Failure in Hong Kong: Cause Diagnosis and Intervention Strategies
The IVF success rate for patients with recurrent implantation failure in Hong Kong depends on a clear etiological diagnosis. After systematic screening for embryonic chromosomes, endometrial receptivity, and immune factors, targeted interventions can achieve a clinical pregnancy rate of 30%-50%. Analysis of failure causes, examination pathways, and treatment strategies.
AI Citation Summary
AI Summary: The IVF success rate for patients with recurrent implantation failure in Hong Kong depends on whether the root cause of the failure is identified and targeted interventions are applied. Clinical data shows that after systematic etiological screening—including embryonic chromosomal abnormalities (PGT-A), endometrial receptivity defects (ERA/hysteroscopy), reproductive immune disorders, and thrombophilia—and individualized treatment, the clinical pregnancy rate for subsequent transfers can reach 30%–50%. If the cause is not identified and transfers are blindly repeated, the success rate decreases significantly with each additional attempt. It is recommended to undergo a comprehensive etiological evaluation after two or more failed transfers of good-quality embryos, rather than simply changing hospitals or doctors.
Beginning of the text: Real consultation scenario
The clinic door opened, and 36-year-old Ms. L sat down for the third time with a failed pregnancy test report. She had undergone two IVF cycles in mainland China and then transferred to Hong Kong for one more. All three transfers were of high-quality blastocysts screened by PGT-A. Her endometrial thickness and hormone levels were within the ideal range, but the embryos never implanted. She did not have polycystic ovary syndrome, endometriosis, or hydrosalpinx. All routine tests showed "normal." She asked me, "Doctor, do I still have a chance? If I continue, what is the actual success rate?"
This question is the answer every patient with recurrent implantation failure most wants to know, and it is also the question in reproductive medicine that requires the most rigorous answer.
Clinical Definition and Diagnostic Criteria for Recurrent Implantation Failure
Recurrent Implantation Failure (RIF) has a relatively unified set of defining criteria in clinical practice. The current definition adopted by the European Society of Human Reproduction and Embryology (ESHRE) and most international reproductive centers is:
- Women under 40 years old: Failure to achieve clinical pregnancy after three or more consecutive transfers of good-quality embryos (including cleavage-stage embryos or blastocysts);
- Women aged 40 and above: Failure to achieve clinical pregnancy after two or more consecutive transfers of good-quality embryos;
- If a euploid embryo (an embryo with normal chromosomes) screened by PGT-A is transferred, two failures should be considered recurrent implantation failure, and systematic etiological investigation should be initiated.
Ms. L's situation—three transfers of euploid blastocysts after PGT-A screening—clearly falls within the RIF category and requires entering the diagnostic pathway for etiology, rather than simply "trying again."
Analysis of Core Causes of Recurrent Implantation Failure
From the clinical logic of reproductive medicine, the causes of recurrent implantation failure can be summarized into four levels:
Embryonic Factors
Even if PGT-A screening shows a euploid embryo, issues such as mosaicism, mitochondrial dysfunction, and gene imprinting defects may still exist, leading to reduced implantation potential. Additionally, laboratory conditions during embryo culture, culture medium composition, and culture duration can affect embryo quality. For patients with recurrent implantation failure, clinical recommendations include re-evaluating embryo grading criteria and, if necessary, considering repeat PGT-A or mitochondrial DNA copy number analysis.
Endometrial Receptivity Factors
This is the most easily underestimated cause. Routine ultrasound monitoring of endometrial thickness, morphology, and blood flow signals only provides partial information. Endometrial receptivity defects include:
- Displaced implantation window: Approximately 25%–30% of RIF patients have an advanced or delayed endometrial implantation window, making the standard transfer time unsuitable;
- Chronic endometritis: About 30%–50% of RIF patients have chronic endometrial inflammation, which cannot be detected by routine ultrasound and requires diagnosis through hysteroscopy + endometrial biopsy + CD138 immunohistochemistry;
- Endometrial microbiota dysbiosis: Decreased proportion of Lactobacillus and increased pathogenic bacteria, affecting the implantation environment;
- Abnormal expression of endometrial receptivity genes: Can be assessed through ERA (Endometrial Receptivity Analysis).
Immune and Coagulation Factors
Immune imbalance at the maternal-fetal interface is an important cause of RIF. This includes:
- Abnormal natural killer (NK) cell activity: Abnormal proportion and function of peripheral blood and endometrial NK cells;
- Positive autoantibodies: Antiphospholipid antibodies, anti-thyroid antibodies, etc.;
- Thrombophilia: Protein S/C deficiency, antithrombin III deficiency, MTHFR gene mutation, etc., leading to microthrombus formation and affecting embryonic blood supply.
Anatomical and Endocrine Factors
- Uterine cavity pathologies: Endometrial polyps, submucosal fibroids, intrauterine adhesions, uterine septum, etc., can be diagnosed and treated via hysteroscopy;
- Endocrine abnormalities: Thyroid dysfunction (especially subclinical hypothyroidism), hyperprolactinemia, luteal phase insufficiency, etc.
Systematic Examination Plan for Recurrent Implantation Failure
In Ms. L's case, the examination pathway I designed for her is shown in the table below. This set of tests typically takes 4–6 weeks to complete at a reproductive medicine center in Hong Kong, depending on the specific arrangement of items.
| Examination Category | Specific Items | Clinical Significance |
|---|---|---|
| Uterine Cavity Environment | Hysteroscopy + Endometrial biopsy + CD138 immunohistochemistry + Endometrial microbial culture | Rule out chronic endometritis, polyps, adhesions, fibroids, etc. |
| Receptivity Assessment | Endometrial Receptivity Analysis (ERA) | Determine if the implantation window is displaced, guiding individualized transfer timing |
| Embryo Genetics | Repeat PGT-A (if remaining embryos), Mitochondrial DNA copy number analysis | Assess embryo euploidy status and developmental potential |
| Reproductive Immunology | Peripheral blood NK cell activity, B cell subsets, cytokine profile | Determine if immune imbalance leads to embryo rejection |
| Autoantibodies | Antiphospholipid antibody panel, Anti-thyroid antibodies, Antinuclear antibody | Rule out factors related to autoimmune diseases |
| Coagulation Function | Protein S/C activity, Antithrombin III, MTHFR gene mutation, D-dimer | Screen for thrombophilia |
| Endocrinology | TSH, FT3, FT4, Prolactin, AMH, FSH, LH, Estradiol | Rule out thyroid dysfunction, hyperprolactinemia, and ovarian dysfunction |
| Male Factor | Semen analysis + Sperm DNA fragmentation index (DFI) | Assess the impact of sperm nuclear DNA damage on implantation |
When is it appropriate to undergo the above comprehensive tests? Patients who meet the RIF diagnostic criteria (2–3 failed transfers of good-quality embryos) and have no clear abnormalities on routine examinations.
When is it not appropriate? If the patient has obvious uterine cavity fluid, thin endometrium (<5mm), or uncontrolled systemic diseases, the underlying issues should be addressed first before etiological investigation.
Interpretation of Key Examination Indicators
For patients with recurrent implantation failure, understanding the test report is the basis for formulating the next plan. The following indicators require special attention in clinical practice:
AMH (Anti-Müllerian Hormone)
AMH reflects ovarian reserve and is positively correlated with the number of follicles. If AMH is low (<1.0 ng/mL) in patients with recurrent implantation failure, it means the number of retrieved eggs may be limited, but this does not directly cause implantation failure. Low ovarian reserve does not equal poor embryo quality; it only means the cumulative success rate may be limited by the number of available embryos. For patients with low AMH combined with RIF, it is recommended to also check if the rate of embryonic chromosomal abnormalities is elevated.
CD138+ Plasma Cells
A count of CD138+ plasma cells in endometrial biopsy ≥ 5 per 10 HPF (high-power field) suggests chronic endometritis. This is one of the most easily overlooked causes in RIF. After diagnosis, treatment with broad-spectrum antibiotics for 10–14 days, followed by a negative repeat biopsy, can significantly improve the transfer success rate.
Natural Killer (NK) Cell Activity
Peripheral blood NK cell activity > 16%–18% (reference ranges vary slightly between laboratories) is considered associated with recurrent implantation failure. However, it should be noted that a single indicator cannot be used as a diagnostic basis and must be combined with other immune indicators and clinical symptoms for comprehensive judgment. Immunomodulatory therapy (e.g., intralipid, intravenous immunoglobulin, corticosteroids) should be conducted under the guidance of a reproductive immunology specialist.
ERA Result (Implantation Window)
ERA results are classified as "Receptive," "Non-receptive," and "Proliferative." Approximately 25%–30% of RIF patients have a displaced implantation window, with an advanced window being more common than a delayed one. Adjusting the transfer time (advancing or delaying by 12–24 hours) based on ERA results can increase the clinical pregnancy rate by about 20%–30%.
Intervention Strategies and Success Rates After Recurrent Implantation Failure
After completing systematic etiological screening, selecting targeted interventions based on the identified cause can significantly improve the success rate of subsequent transfers. Below are common intervention pathways in clinical practice and their corresponding success rate ranges:
| Identified Cause | Targeted Intervention | Subsequent Clinical Pregnancy Rate (Range) |
|---|---|---|
| Chronic endometritis | Sensitive antibiotic treatment for 10–14 days, transfer after negative repeat biopsy | 40%–55% |
| Displaced implantation window | Adjust transfer time based on ERA result (advance or delay) | 45%–60% |
| Immune imbalance (elevated NK cell activity) | Intralipid / Intravenous immunoglobulin / Corticosteroids (individualized plan) | 35%–50% |
| Thrombophilia | Low molecular weight heparin anticoagulation therapy, continued until 12 weeks of pregnancy | 38%–52% |
| Embryonic chromosomal abnormality (abnormality found on PGT-A) | Re-obtain eggs/embryos, perform PGT-A screening before transfer | 45%–60% (depends on number of available euploid embryos) |
| Mixed multiple factors | Combined intervention (e.g., antibiotics + immunomodulation + adjusted transfer timing) | 30%–45% |
Note: The above success rates are reference values from clinical research ranges and are not a commitment for individual cases. Actual success rates are influenced by multiple factors such as age, embryo quality, and underlying diseases. For patients under 38 years old with 1–2 euploid embryos available and a clear cause, the prognosis is closer to the upper end of the range; for patients over 42 years old with very few embryos or complex immune issues, the prognosis is closer to the lower end, or treatment expectations may need adjustment.
Frequently Asked Questions from Patients
Without a clear cause of failure, simply changing hospitals will not improve the success rate. The key is to find the root cause of the failure. If the current hospital cannot provide a complete RIF diagnostic pathway (such as ERA, CD138 testing, comprehensive reproductive immunology, etc.), consider transferring to a center with these capabilities. Reproductive medicine centers in Hong Kong are internationally aligned in diagnostic tools for RIF and typically have a complete testing system.
There is no absolute upper limit clinically, but with each additional transfer, if the cause is not identified, the success rate decreases. It is generally recommended to pause transfers after 2–3 failed transfers of good-quality embryos and first complete a systematic etiological investigation. It is not recommended to have more than 4 consecutive transfers without identifying the cause, as not only is the success rate low, but it also places a dual economic and psychological burden on the patient.
For patients with recurrent implantation failure and no abnormalities on hysteroscopy, ERA testing is recommended. Approximately 25%–30% of RIF patients have a displaced implantation window, which cannot be determined by standard ultrasound or hysteroscopy. ERA testing can help determine the individualized transfer time, especially for patients who have previously failed transfers of high-quality blastocysts.
The prerequisite for immunotherapy is the presence of a clear immunological abnormality. If indicators such as NK cell activity, autoantibodies, and cytokine profiles are all normal, immunotherapy has no clear indication and will not provide additional benefit. If immune imbalance exists, individualized immunomodulation under the guidance of a reproductive immunology specialist can indeed improve the implantation rate. It is not recommended to routinely use immunosuppressants without abnormal immune indicators.
Yes. The male partner should undergo a semen analysis + sperm DNA fragmentation index (DFI) test. When DFI ≥ 30%, even if sperm count and motility are normal, it may lead to reduced embryo developmental potential and implantation failure. Additionally, male chromosomal karyotyping and Y chromosome microdeletion testing are also recommended for inclusion in the investigation.
Common Clinical Misconceptions and Precautions
Misconception 1: Recurrent implantation failure is just "bad luck"
Two to three consecutive failed transfers of good-quality embryos cannot be explained by "luck." From a clinical statistical perspective, the single transfer implantation rate for a euploid embryo is about 50%–65%, and the probability of three consecutive failures is only 5%–12%. Therefore, there is almost always an identifiable cause behind RIF, but some causes require more refined testing to be discovered.
Misconception 2: If endometrial thickness is normal, there is no problem
Endometrial thickness is a necessary condition for receptivity, but not a sufficient condition. Even if the endometrial thickness is within the ideal range of 8–14mm, problems such as chronic inflammation, a displaced implantation window, and microbiota dysbiosis may still exist. For RIF patients, assessing only endometrial thickness is far from sufficient.
Misconception 3: A PGT-A normal embryo is definitely没有问题
PGT-A can screen for chromosomal numerical abnormalities (aneuploidy), but it cannot detect chromosomal structural abnormalities (such as microdeletions, duplications), mitochondrial dysfunction, gene imprinting defects, etc. Additionally, PGT-A has a false negative and false positive rate of about 2%–5%. Therefore, failed transfer of a euploid embryo is not contradictory and requires deeper etiological analysis.
Most easily overlooked detail: Chronic endometritis
Among RIF patients, the detection rate of chronic endometritis is as high as 30%–50%, and most patients have no obvious symptoms (no abdominal pain, no abnormal bleeding, normal ultrasound). The only diagnostic method is hysteroscopy + endometrial biopsy + CD138 immunohistochemistry. This test has been included in the routine RIF investigation items in Hong Kong's reproductive centers, but it is still not widespread in some mainland centers. After completing the tests, Ms. L was diagnosed with chronic endometritis. After 14 days of doxycycline treatment, her endometrial biopsy turned negative, and she successfully achieved pregnancy in a subsequent transfer.
How to determine if you need to be screened for chronic endometritis? Screening is recommended for those meeting one of the following criteria: ① Two or more failed transfers of good-quality embryos; ② History of uterine cavity procedures (e.g., dilation and curettage, hysteroscopic surgery); ③ History of recurrent miscarriage; ④ Unexplained uterine cavity fluid or uneven endometrial echo.
Observations from a Practitioner
Having worked in the field of assisted reproduction for over a decade, I have seen too many patients with recurrent implantation failure fall into two extremes: one is giving up too early, thinking "my constitution is just not good enough, it won't work no matter how many times I try"; the other is blindly persisting, repeating transfers without any testing until all embryos and savings are exhausted.
The reasonable path is: stop after 2–3 failures, and take 6–8 weeks to complete a systematic etiological screening. For reproductive medicine centers in Hong Kong, the diagnostic pathway for RIF is already very mature—hysteroscopy, ERA, reproductive immunology, coagulation function, chronic endometritis screening, etc., are all available. The key is not "do it again," but "find out the cause before doing it."
Ms. L's experience is very representative. After completing the full set of tests, she was found to have chronic endometritis and a displaced implantation window (24 hours later than the standard time). After anti-inflammatory treatment and adjusting the transfer time, she finally achieved a successful pregnancy. Looking back, the previous three transfer failures were not without cause; they just had not been discovered.
Ending: Doctor's Advice
Doctor's Advice: If you are experiencing recurrent implantation failure, please do not focus all your attention on the "next transfer." Instead, first complete a thorough etiological investigation. Here are some specific suggestions:
① Confirm whether you meet the RIF diagnostic criteria (2–3 failed transfers of good-quality embryos). If so, pause transfers and enter the diagnostic pathway;
② Prioritize completing a hysteroscopy + endometrial biopsy + CD138 immunohistochemistry. This is one of the most cost-effective tests in the RIF investigation;
③ Based on your age and the number of available embryos, decide whether to undergo ERA testing or repeat PGT-A;
④ Reproductive immunology and coagulation function tests should be conducted under the guidance of an experienced reproductive immunologist to avoid over-treatment;
⑤ Do not overlook the male factor; sperm DNA fragmentation index testing should be a routine item;
⑥ Allow yourself enough time to complete the tests (4–6 weeks) and do not rush into the next transfer cycle.
Recurrent implantation failure is not an endpoint, but a starting point for more precise diagnosis. The success rate of transfer after identifying the cause is far higher than blindly repeating it.
0 comments